Skip to content
Subscriber Only
Opinion
Max Nisen

Gilead Needs More Than a Steady Hand From Its New CEO

Daniel O’Day has tough decisions to make about how to deploy the company’s resources.

He has the right background. Now comes the tough part.

He has the right background. Now comes the tough part.

Photographer: Chris Ratcliffe/Bloomberg

Gilead Sciences Inc. has been in leadership limbo for five uncomfortable months; replacing a CEO and chairman combination that turned the company into a giant isn’t easy. 

So the hiring on Monday of Roche Holding AG pharma head Daniel O’Day comes as a significant relief. It ends uncertainty, for sure. More important, O’Day is clearly qualified. He’s a veteran of one of the world’s most successful pharma firms and has deep expertise with cancer medicines, a priority for Gilead.